The vitamin D receptor polymorphism in the translation initiation codon is a risk factor for insulin resistance in glucose tolerant Caucasians by Chiu, Ken C et al.
BMC Medical Genetics (2001) 2:2 http://www.biomedcentral.com/1471-2350/2/2
BMC Medical Genetics (2001) 2:2 Research article
The vitamin D receptor polymorphism in the translation initiation  
codon is a risk factor for insulin resistance in glucose tolerant 
Caucasians
Ken C Chiu*1, Lee-Ming Chuang2 and Carol Yoon1
Address:  1Division of Endocrinology, Diabetes and Hypertension,  Department of Medicine, University of California, Los Angeles, School of  
Medicine, Los Angeles, California, USA and 2Department of Internal Medicine and Graduate Institute of  Clinical Medicine, National Taiwan 
University Hospital, Taipei, Taiwan
E-mail: Ken C Chiu* - kchiu@mednet.ucla.edu; Lee-Ming Chuang - leeming@ha.mc.ntu.edu.tw; Carol Yoon - kclab@mednet.ucla.edu
*Corresponding author
Abstract
Background:  Al though v itamin D rece ptor (V DR ) polymorphis ms  have  be en shown t o be
associated with abnormal glucose metabolism, the reported polymorphisms are  unlikely to have
any biological consequences. The VDR gene has two potential  translation initiation sites. A T-to-
C polymorphism has been noted in the first  ATG (f allele), abolishing the first translation initiation
site and resulting  in a peptide lacking the first three amino acids (F allele). We examined the  role
of this polymorphism in insulin sensitivity and beta cell function. This  study included 49 healthy
Caucasian subjects (28 females, age 28 ±  1 years  old, body mass index 24.57 ±  0.57 kg/m2, waist-
hip ratio 0.81  ±  0.01 cm/cm). They were all normotensive (less than 140/90 mmHg) and  glucose
tolerant, which was determined by a standard 75-gm oral glucose  tolerance test. Their beta cell
funct ion (%B) and insulin s ensi tivit y (%S ) were   calculate d bas ed on the  H ome os tasis  M od el
A s s e s s m e n t  ( H O M A ) .  Th e i r  g e n o t y p e s   w e r e  d e t e r m i n e d  b y  a  p o l y m e r a s e  c h a i n  r e a c t i o n -
restriction fragment length  polymorphism analysis. Phenotypes were compared between genotypic
groups.
Results:  There were 18 FF, 21 Ff, and 10 ff subjects. Since only 10 ff subjects were  identified, they
were pooled with the Ff subjects during analyses. The FF and  Ff/ff groups had similar glucose levels
at each time point before and after a  glucose challenge. The Ff/ff group had higher insulin levels
than the FF group  at fasting (P=0.006), 30 minutes (P=0.009), 60 minutes (P=0.049), and 90
minutes (P=0.042). Furthermore, the Ff/ff group also had a larger insulin area  under the curve than
the FF group (P=0.009). While no difference was noted in  %B, the Ff/ff group had a lower %S than
the FF group (0.53 vs. 0.78, P=0.006).  A stepwise regression analysis confirmed that the Fok I
polymorphism  was an independent determinant for %S, accounting for 29.3% of variation in %S
when combined with waist-hip ratio.
Conclusions:  We report that the Fok I polymorphism at the VDR gene locus is  associated with
insulin sensitivity, but has no influence on beta cell function  in healthy Caucasians. Although this
polymorphism has been shown to affect the  activation of vitamin D-dependent transcription, the
molecular basis of the  association between this polymorphism and insulin resistance remains to be
determined.
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Introduction
Although conflicting findings about bone mineral densi-
ty (BMD) in patients  with type 2 diabetes have been re-
ported, there are substantial data which  support the
notion that type 2 diabetes is associated with increased
BMD [1,2,3]. The  Rotterdam Study [2], which involved
5,931 subjects,  including 243 men and 355 women with
type 2 diabetes, provides the most  convincing evidence.
They found that diabetic men and women had increased
BMD  independent of age, obesity, the use of estrogen,
thiazide, or loop diuretics,  impairment in the ability of
daily living, and smoking [2 ]. Furthermore, hyperin-
sulinemia has been reported to be associated with an  in-
creased BMD in diabetic [4] and non-diabetic subjects
[5]. From the Rancho Bernardo Study [5], the level of
fasting insulin was significantly and positively  associat-
ed with BMD in non-diabetic female subjects, where
each 10 µ U/ml  increase in fasting insulin level was asso-
ciated with an increase of BMD by  0.33 g/cm2 in the ra-
dius and 0.57 g/cm2 in the spine.  However, no
independent association between fasting insulin level
and BMD was  noted in males [5]. Since fasting insulin
level is an  indicator of insulin resistance, it is tempting
to hypothesize that insulin  resistance (decreased insulin
sensitivity) is associated with increased BMD.
BMD is known to have strong genetic determinants. Our
understanding of the  relationship between BMD and
VDR gene polymorphism is based on a twin study of  se-
rum osteocalcin level [6]. The synthesis of  osteocalcin,
the most abundant non-collageous protein in bone, is in-
duced by  calcitriol (the active form of vitamin D)
through the VDR. Since a variation in  serum osteocalcin
level was shown to have a strong genetic component me-
diated  through the VDR, the relationship between VDR
polymorphisms and serum  osteocalcin level was found.
Furthermore, this relationship was shown to be  inde-
pendent of age or menopausal effect [7].  Subsequently,
the VDR gene polymorphisms were found to account for
75% of the  total genetic effect on BMD in healthy people
[8].  However, to date there are more than 50 studies on
the relationship between VDR  gene polymorphisms and
BMD [9]. About half of the studies  found a significant as-
sociation, and the other half found no association [9].
The most convincing evidence comes from a study of
peak BMD  in a group of pre-pubertal girls [10], which
confirms  the relationship between VDR gene polymor-
phism and BMD.
Since the VDR is expressed in tissues, namely muscle
and pancreatic islets  [11,12,13,14], which are involved in
the regulation of glucose  metabolism, we hypothesized
that the VDR gene could play a role in glucose  metabo-
lism. In this study, we examined the role of the Fok I  pol-
ymorphism in the translation initiation codon of the
VDR gene in 49 healthy,  glucose tolerant Caucasians
who underwent a standard oral glucose tolerance  test.
The insulin sensitivity and beta cell function were esti-
mated using a  homeostasis model assessment (HOMA)
[15]. We found that  the Fok I polymorphism is associat-
ed with insulin resistance in a  Caucasian population.
Results
Characteristics of the study population
Since hypertension is associated with insulin resistance
[16], only those with normal blood pressure (systolic
blood pressure less  than 140 mmHg and diastolic blood
pressure less than 90 mmHg) were enrolled  into the
study. Because we were also concerned about the effect
of glucose  toxicity on beta cell function and insulin sen-
sitivity [17], all subjects underwent a standard 75-gm
oral glucose tolerance  test. Only those subjects with a
fasting plasma glucose level less than 6.1 mM,  interval
plasma glucose levels (at 30, 60, and 90 minutes) less
than 11.1 mM,  and two-hour plasma glucose level less
than 7.8 mM were enrolled in this  study.
This study included 49 healthy Caucasian subjects, of
which 28 were female.  Clinical features of the subjects
were: mean age 28 years old (range: 19-39  years), mean
body mass index 24.26 kg/cm2 (17.58-34.26 kg/cm2),
mean waist-hip ratio 0.80 cm/cm (0.65-1.03 cm/cm),
mean systolic  blood pressure 113 mmHg (94-135 mm-
Hg), mean diastolic blood pressure 67 mmHg  (53-83
mmHg), mean fasting plasma glucose level 4.71 mM
(3.88-5.54 mM), mean  30-minute post challenged plas-
ma glucose level 7.40 mM (5.34-9.66 mM), mean  60-
minute post challenged plasma glucose level 9.09 mM
(3.79-10.20 mM), mean  90-minute post challenged
plasma glucose level 6.30 mM (3.12-9.02 mM), and
mean  two-hour post challenged plasma glucose level
5.71 mM (2.94-7.60 mM).
Genotype, phenotype, and biochemical association
After genotyping, we identified 18 FF, 21 Ff, and 10 ff
subjects. In this  Caucasian population, the allele fre-
quency was 58% for the F allele and 42% for  the f allele.
The distribution of genotypes was in compliance with the
Hardy-Weinberg equilibrium (p=0.873). Since only 10 ff
subjects were  identified, they were pooled with the Ff
subjects. Two groups (FF vs. Ff/ff)  had compatible gen-
der distribution, age, body mass index, systolic and  di-
astolic blood pressure, fasting lipid profiles and fasting
plasma glucose  level (Table 1). However, the Ff/ff sub-
jects had a higher  mean waist-hip ratio and a higher
mean fasting plasma insulin level, compared  to the FF
subjects (p=0.042 and p=0.006, respectively). These re-
sults indicate  that the Ff/ff subjects are more obese and
more insulin resistant than the FF  subjects.BMC Medical Genetics (2001) 2:2 http://www.biomedcentral.com/1471-2350/2/2
Beta cell function (%B) and insulin sensitivity (%S) were
estimated from the  HOMA based on the average of three
fasting plasma glucose and insulin levels  before the oral
glucose tolerance test. No difference was noted in %B be-
tween  the two groups (p=0.23). However, there was a
drastic difference in %S between  the two groups
(p=0.006). After an oral glucose load (Figure  1), the Ff/
ff subjects had similar plasma glucose levels at each time
point compared to the FF subjects. However, the Ff/ff
subjects had higher  postchallenged insulin levels at 30,
60, and 90 minutes than the FF subjects  (p=0.009,
p=0.049, and p=0.041, respectively). Furthermore, the
Ff/ff subjects  had a higher insulin area under the curve
than the FF subjects (p=0.009). These  results again in-
dicate that the Ff/ff subjects are more insulin resistant
than  the FF subjects.
Stepwise regression analysis
Various covariates have been shown to affect either beta
cell function or  insulin sensitivity or both. To examine
the influence of the available  covariates in addition to
the Fok I polymorphism on beta cell function  and insulin
sensitivity, we employed a stepwise regression analytical
approach.  Age, gender, body mass index, waist-hip ratio,
and systolic and diastolic blood  pressure were entered
into the model and a backward stepwise regression  anal-
ysis was performed. It revealed that the Fok I polymor-
phism was an  independent determinant for %S, but not
for %B (Table 2).  The Fok I polymorphism, combined
with waist-hip ratio, explained 29.3%  of the variance in
%S. This result confirms that this polymorphism is an
independent risk factor for insulin resistance.
Discussion
We found that in healthy, normotensive Caucasian sub-
jects with normal  glucose tolerance, the Fok I polymor-
phism in the vitamin D receptor  gene accounted for
15.2% of the variance in %S, but had no impact on %B.
Although the Ff/ff subjects were more obese than the FF
subjects (p=0.042 for  waist-hip ratio), the difference in
%S between the two groups decreased after  adjusting for
waist-hip ratio (0.50 vs. 0.69 before and 0.52 vs. 0.65 af-
ter  adjusting for waist-hip ratio). However, this poly-
morphism remained an  independent determinant for
%S after adjusting for waist-hip ratio (p=0.039 Figure
2).  Therefore, we concluded that the Fok I polymor-
phism was a risk factor  for insulin resistance, independ-
ent of obesity.
The allelic frequencies of the present study (58% for the
F allele and 42%  for the f allele) are very similar to the
reported frequencies in a Japanese  (56% for the F allele
and 44% for the f allele) and a Caucasian (59% for the F
allele and 41% for the f allele) population [18,19]. In the
present study, we pooled the ff subjects with Ff  subjects
for its small sample size (10 ff vs. 18 Ff and 21 FF). To ex-
amine  whether there is a difference among the three
genotypic groups, we examined the  influence of geno-
types on %S and %B by ANOVA. We found a significant
Table 1: Clinical features and glycemic parameters by the VDR genotypes
Ff/ff FF
Mean (n) (95% CI) Mean (n) (95% CI)
N3 1 1 8
Gender F/M 16/15 12/6
Age year 28 (26, 30) 27 (24, 30)
Body mass index kg/m2 25.01 (23.45, 26.56) 23.82 (22.06, 25.59)
Waist-hip ratio 1 cm/cm 0.83 (0.79, 0.86) 0.77 (0.73, 0.82)
Systolic blood pressure mmHg 113 (110, 117) 112 (107, 117)
Diastolic blood pressure mmHg 68 (65, 70) 66 (62, 70)
Triglycerides mM 1.357 (1.083, 1.631) 1.045 (0.731, 1.360)
Total cholesterol mM 4.055 (3.757, 4.353) 4.093 (3.725, 4.461)
HDL cholesterol mM 1.226 (1.108, 1.343) 1.322 (1.132, 1.512)
LDL cholesterol mM 2.373 (2.106, 2.641) 2.392 (2.099, 2.685)
Oral glucose tolerance test
Fasting plasma glucose mM 4.75 (4.64, 4.85) 4.63 (4.43, 4.84)
Fasting plasma insulin 2 pM 70 (63, 77) 54 (46, 62)
%B 162 (144, 180) 152 (112, 192)
%S 3 0.53 (0.47, 0.59) 0.78 (0.52, 1.06)
1 p=0.042 for geometric means; 2 p=0.006 for  geometric means; 3 p=0.006 for geometric meansBMC Medical Genetics (2001) 2:2 http://www.biomedcentral.com/1471-2350/2/2
difference  in %S (p=0.016) and again no difference in
%B (p=0.408). However, no difference  in %S was noted
between the Ff and ff groups (p=0.159). The main differ-
ence in  %S is between the FF and Ff groups (p=0.007).
Although we cannot exclude the  possibility of inade-
quate power to detect the difference from the present
sample size, this observation is consistent with the func-
tional study of the  Fok I polymorphism in cultured hu-
Figure 1
Plasma glucose and insulin levels during the oral glucose tolerance  test by the FokI polymorphism at the vita-
min D receptor gene locus. The  data presents arithmetic means ±  standard errors. The Ff/ff group is shown  as the line
with the solid dots and The FF group is shown as the line with open  dots. The plasma insulin levels were different between the
two groups at  fasting (a, p=0.006), 30 (b, p=0.009), 60 (c, p=0.049) and 90 (d, p=0.041)  minutes. The insulin areas under the
curve were also different (p=0.009)  between the two groups.
Table 2: Stepwise regression analysis
Dependent Variable Covariate  Entered Covariate Removed r 2 p
%S 0.293
Waist-hip ratio 0.004
Fok I polymorphism 0.039
Diastolic blood pressure 0.121
Body mass index 0.140
Systolic blood pressure 0.152
Gender 0.566
Age 0.715
%B -
Age 0.146
Fok I polymorphism 0.229
Waist-hip ratio 0.475
Body mass index 0.715
Gender 0.786
Diastolic blood pressure 0.916
Systolic blood pressure 0.985BMC Medical Genetics (2001) 2:2 http://www.biomedcentral.com/1471-2350/2/2
man peripheral blood mononuclear  cells [20]. In this
functional study, they compared the  inhibitory effect of
1,25-dihydroxyvitamin D3 on the growth of  cultured hu-
man peripheral mononuclear cells isolated from subjects
with  different Fok I genotypes and found significant dif-
ferences among the  three genotypes, but found no differ-
ence between the Ff and ff groups [20].
Obesity is well known to be associated with insulin re-
sistance [21]. In the present study, we also found that the
Fok  I polymorphism was associated with obesity as-
sessed by waist-hip ratio but  not by body mass index
(Table 1). However, the  association between the Ff/ff
genotypes with both insulin resistance and  obesity
prompted us to further examine the interaction among
this polymorphism,  obesity, and insulin resistance. Mul-
tivariate analysis revealed that this  polymorphism had
no independent impact on waist-hip ratio (p=0.1468) af-
ter  adjustment for age (p=0.0203), gender (p=0.0007)
and body mass index (p <  0.0001), while systolic and di-
astolic blood pressure had also no impact on  waist-hip
ratio (p=0.5549 and p=0.3806, respectively). However,
from the  multivariate analysis result of %S (Table 2), we
concluded that this polymorphism had an important im-
pact on insulin  sensitivity, which was independent of the
influence of waist-hip ratio.  Although gender was ex-
cluded as an independent covariate for %S in the present
study after adjustment for waist-hip ratio, which was af-
fected by gender, the  interaction between gender and
this polymorphism, if any, needs to be addressed  in a
study with a much larger sample size.
The role of VDR gene polymorphisms has been exam-
ined in four groups of  diabetic patients, however their
roles in insulin sensitivity have not been  examined. In 93
Southern Indian families with type 1 diabetes, transmis-
sion  disequilibrium testing analysis demonstrated the
preferential transmission of  the "b" allele of the Bsm I
polymorphism to affected subjects [22]. However, it was
less certain for the Taq I and  Apa I polymorphisms in
this sample set. Nonetheless, this study  indicates that
the Bsm I polymorphism at the VDR gene locus is a risk
factor of type 1 diabetes. In a study of 152 Caucasian fam-
ilies with type 1  diabetes, there was an excessive trans-
mission of bT and bAT extended haplotypes  to affected
individuals but no evidence of excessive transmission of
Taq  I and Apa I alleles alone [23]. Recently,  we con-
firmed the association of this marker with type 1 diabetes
in a Taiwanese  population [24]. These studies in two dif-
ferent  populations indicate that the Bsm I polymor-
phism at the VDR gene locus  confers susceptibility to
type 1 diabetes. The study of type 2 diabetes with  the
VDR gene included 164 Bangladesh Asians who were at
risk for type 2  diabetes and 25% of them were either di-
abetic or impaired glucose tolerant. An  association be-
tween the Apa I polymorphism and insulin secretion
index  was noted [25]. These studies suggest that the
VDR gene  locus is a genetic marker for both type 1 and
type 2 diabetes.
Since the Bsm I polymorphism is located in intron 7, the
Apa  I polymorphism in intron 8, and the Taq I polymor-
phism in exon 9  within the 3'-untranslated region of the
VDR gene, they are less likely to have  any biological con-
sequences in causing the disease and affecting glucose
metabolism. Furthermore, functional studies of these
polymorphisms show no  clearly demonstrable differ-
ence among them [26,27,28,29]. The  T-to-C transition
polymorphism at the translation initiation codon of the
human  VDR gene not only destroys a Fok I site but also
abolishes the first  translation initiation codon of this
gene. The alternative translation  initiation codon, which
also adheres the first-AUG rule by Kozak [30], is located
downstream by three amino acids. In the  present study,
we examined the Fok I polymorphism, which not only
affects the translation of the peptide, but also affects the
biological  activity tested in Hela Cells [31]. This T-to-C
transition resulted in the synthesis of a smaller (F allele,
three amino acids  less than the f allele) protein with in-
creased vitamin D-dependent  transcriptional activation
[31]. In addition, the  different response to 1,25-dihy-
droxyvitamin D is also demonstrated in cultured  human
peripheral blood mononuclear cells from subjects with
different Fok  I genotypes [20]. We found that the sub-
jects with  homozygous F allele had increased insulin
sensitivity compared to those with  the f allele.
Although the molecular basis of this association is un-
clear, the study of  the relationship between the level of
vitamin D and glucose tolerance [32] provides some in-
sight to the underlying mechanism. Glucose  tolerance
and vitamin D level were assessed in 142 elderly Dutch-
men. Fasting  insulin and postchallenged insulin levels
decreased with increased vitamin D  levels [32]. As a
higher insulin level is a surrogate  for decreased insulin
sensitivity, their observation suggests that a higher  vita-
min D level is associated with increased insulin sensitiv-
ity. Since vitamin  D binds to the vitamin D receptor to
initiate the downstream action, a higher  vitamin D level
would lead to an increase in vitamin D-dependent tran-
scription  activation. Our observation that the subjects
with homozygous F alleles  (associated with an increased
activity) are more insulin sensitive than those  with the f
allele is consistent with the notion above.
Our original hypothesis was that the allele, which is asso-
ciated with  increased BMD, was also associated with
higher insulin levels and insulin  resistance. However,
since the F allele is associated with increased BMD
[31,33], our observation of the  association between the FBMC Medical Genetics (2001) 2:2 http://www.biomedcentral.com/1471-2350/2/2
allele and increased insulin sensitivity is not  consistent
with our original hypothesis. On the other hand, not all
reports  support the association between the F allele and
increased BMD [34,35]. Nonetheless, our observation
shows that  this polymorphism is an independent deter-
minant for insulin sensitivity and is  in agreement with
the notion that a higher level of vitamin D is associated
with increased insulin sensitivity [32]. Furthermore  ad-
ditional studies in the Caucasian and other ethnic popu-
lations are  required.
In the present study, we report an association between a
polymorphism at the  translation initiation codon of the
human VDR gene and insulin sensitivity in  glucose tol-
erant and normotensive Caucasians. This polymorphism
is an  independent determinant of insulin sensitivity, ex-
plaining 15.2% of the  variance in %S and with waist-hip
ratio, explaining 29.3% of the variance in  %S. Although
the speculated mechanism of our observation is in agree-
ment with  the published association between vitamin D
levels and insulin sensitivity,  further studies are re-
quired to confirm our observation in other ethnic groups
as well as in another Caucasian population. To explore
the underlying molecular  basis of the Fok I polymor-
phism at the VDR gene locus, as well as the  association
between vitamin D level and insulin sensitivity, also war-
rants  further study.
Subjects, materials and methods
Study subjects
We confirm that the study has complied with the recom-
mendations of the  Declaration of Helsinki. The study
was approved by the institutional review  board and a
written informed consent was obtained from each partic-
ipant at the  beginning of the study. Subjects were re-
cruited through an advertisement on a  campus media of
this institution. Only healthy subjects were invited to
participate in this study. They were prescreened via tele-
phone and confirmed  again on the day of the visit. They
were biologically unrelated.
Oral glucose tolerance test and physical examination
Subjects were instructed to fast for at least 14 hours be-
fore the study  visit. On the morning of the visit, an ind-
welling angiocatheter was inserted  into an antecubital
vein. All subjects had fasting blood samples drawn at -15,
-10, and -5 minutes. These samples were used for glu-
cose, insulin, lipid  measurement and genomic DNA iso-
lation. Fasting plasma glucose and insulin  levels were
calculated as the average of three fasting samples. After
the oral  administration of 75-gm glucose, postchal-
lenged blood samples were drawn at 30,  60, 90, and 120
minutes for glucose and insulin measurements. A limited
physical examination was performed on all study partic-
ipants, including  measurements of weight, height, waist,
hip, and blood pressure. After resting  quietly for 30 min-
utes, three consecutive measurements of systolic and  di-
astolic blood pressures were taken one minute apart, and
the average of the  three measurements was reported.
DNA extraction and genotyping of the Fok I polymorphism
Genomic DNA was extracted from peripheral lym-
phocytes as previously  described [36]. The genomic
DNA fragment flanking the  Fok I polymorphism was
amplified using two primers flanking exon 2 of  the VDR
gene: AGCTGGCCCTGGCACTGCTCTGCTCT and AT-
GGAAACACCTTGCTTCTTCTCCCTC.  Polymerase chain
reaction (PCR) was carried out in a total volume of 11 µ l
containing 0.5 pM of each primer, 0.2 mM dNTP, 2 mM
MgCl2, 5%  dimethysulphoxide (DMSO), 0.275 U Taq
polymerase, 50 mM KCl, 10 mM Tris-HCl pH  8.3, and
0.001% gelatin. The region of interest was amplified by
an initial  denaturation at 94° C for 5 minutes, 35 cycles
of denaturation at 94° C  for 30 seconds, annealing at
60° C for 30 seconds, and extension at  72° C for 30 sec-
onds, and concluded with a final extension at 72° C for  10
minutes. Then, 5 µ l of the PCR product (265 base pairs)
was digested in  15-µ l of reaction volume containing 1 U
of Fok I (New England  Biolabs Inc., Beverly, Massachu-
setts, USA) with the buffer supplied by the  vender. The
digested PCR products were resolved on 2.0% agarose
gels. Fok  I digested the first ATG and yielded two prod-
ucts, 69 and 196 base pairs  (f allele), while the T to C
transition destroyed the Fok I site (F  allele).
Statistical analysis
SYSTAT version 8.0 for Windows of the SPSS Inc. (Chi-
cago, Illinois, USA) was  used for statistical analysis. Var-
Figure 2
Ad justed insulin sensit ivit y ( %S) by  t he F ok I poly-
m o r p h i s m  a t  t h e   v i t a m i n  D  r e c e p t o r  g e n e  l o c u s .
They were logarithmically transformed before  analysis and
expressed as geometric mean ±  standard error. Insulin  sen-
sitivity was adjusted for waist-hip ratio as described in the
methods and  results sections and in Table 2.BMC Medical Genetics (2001) 2:2 http://www.biomedcentral.com/1471-2350/2/2
iables with skewed distributions were  logarithmically
transformed before analysis. The variables transformed
were  body mass index, waist-hip ratio, plasma insulin
levels, insulin area under the  curve, %B, and %S. Data
were presented as mean (or geometric means when  ap-
propriate) with 95% confidence intervals, unless other-
wise specified.  Two-sided t-tests or chi-square tests were
used to evaluate the differences  between the two groups.
To determine the interaction of the genotype of  interest
with the other covariates, a stepwise regression analysis
was  performed with a backward option and an alpha-to-
remove or alpha-to-enter  setting at 0.10. The covariates
with the highest p value were removed one at a  time, un-
til all the remaining covariates had a p value less than
0.10.
Abbreviations
HOMA, Homeostasis Model Assessment; VDR, vitamin
D receptor; BMD, bone  mineral density; PCR, polymer-
ase chain reaction.
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